PureTech Health plc (PRTC)

NASDAQ: PRTC · Real-Time Price · USD
15.82
-0.68 (-4.12%)
Sep 3, 2025, 4:00 PM - Market closed
-4.12%
Market Cap377.79M
Revenue (ttm)6.39M
Net Income (ttm)50.68M
Shares Out 240.25M
EPS (ttm)0.20
PE Ratio7.45
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,318
Open15.82
Previous Close16.50
Day's Range15.82 - 15.88
52-Week Range13.30 - 24.99
Beta0.86
AnalystsBuy
Price Target45.00 (+184.45%)
Earnings DateAug 28, 2025

About PRTC

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 56
Stock Exchange NASDAQ
Ticker Symbol PRTC
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to one analyst, the rating for PRTC stock is "Buy" and the 12-month stock price target is $45.0.

Price Target
$45.0
(184.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript

PureTech Health plc (NASDAQ:PRTC) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co...

6 days ago - Seeking Alpha

PureTech Health plc – Half-Year Report

BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.

7 days ago - Business Wire

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.

14 days ago - Business Wire

PureTech Health: Notice of Half-Yearly Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.

17 days ago - Business Wire

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.

21 days ago - Business Wire

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

BOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases.

23 days ago - Business Wire

PureTech Announces Leadership Transition

BOSTON--(BUSINESS WIRE)--PureTech Announces Leadership Transition.

7 weeks ago - Business Wire

PureTech Announces Board Change

BOSTON--(BUSINESS WIRE)--PureTech Announces Board Change.

2 months ago - Business Wire

PureTech Health: Results of Annual General Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.

2 months ago - Business Wire

PureTech to Present at the Jefferies Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.

3 months ago - Business Wire

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF).

4 months ago - Business Wire

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

BOSTON--(BUSINESS WIRE)--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference.

4 months ago - Business Wire

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call April 30, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior Vice President, Communications Bharatt Chowrira - Chief Executive O...

4 months ago - Seeking Alpha

PureTech Announces Annual Results for Year Ended December 31, 2024

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024.

4 months ago - Business Wire

PureTech Health: Notice of Results

BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.

4 months ago - Business Wire

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

BOSTON--(BUSINESS WIRE)--PureTech Appoints Peel Hunt as Joint UK Corporate Broker.

5 months ago - Business Wire

PureTech Health plc Statement Regarding Press Speculation

BOSTON--(BUSINESS WIRE)--Statement regarding press speculation.

5 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair.

6 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform.

7 months ago - Business Wire

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

BOSTON--(BUSINESS WIRE)--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine.

7 months ago - Business Wire

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML).

8 months ago - Business Wire

PureTech Appoints UBS as UK Corporate Broker

BOSTON--(BUSINESS WIRE)--PureTech Appoints UBS as UK Corporate Broker.

8 months ago - Business Wire

PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

BOSTON--(BUSINESS WIRE)--PureTech's Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial.

9 months ago - Business Wire

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024.

9 months ago - Business Wire

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting.

9 months ago - Business Wire